Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib in Relapsed/Refractory T-LGLL
NCT05676710Phase 1Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linperlisib in T-cell large granular lymphocytic leukemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Response Rate at 8 weeks. Started Feb 2023; status: completed.
02
Drugs
linperlisib
03
Conditions
T-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on NCT05676710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676710.